A biomarker study of XBIO-101 in triple negative breast cancer (TNBC)

Trial Profile

A biomarker study of XBIO-101 in triple negative breast cancer (TNBC)

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Cridanimod (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 10 Apr 2017 New trial record
    • 03 Apr 2017 According to a Xenetic Biosciences media release, the company has recently recently filed a protocol under its existing investigational new drug application for a biomarker study of XBIO-101 in triple negative breast cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top